Methotrexate (MTX) is used in the treatment of a variety of diseases such as rheumatoid arthritis, dermatomyositis, juvenile rheumatoid arthritis and chronic plaque psoriasis. It has been well documented that there is a risk of development of lymphomas in these patients although none have been reported in patients of psoriasis treated with methotrexate. A 58-year-old male patient, a known case of psoriasis since 1994, had been receiving treatment with a low dose of MTX, 5 mg weekly for ten years intermittently (7-8 months/year). The cumulative dose of MTX taken was 1.5 gm. He developed high-grade fever with cervical lymphadenopathy that was nonresponsive to routine line of management. Lymph node biopsy revealed the presence of mixed cellularity type of Hodgkin's lymphoma. CT scan showed cervical, mediastinal and abdominal lymphadenopathy. The patient responded well to withdrawal of MTX and chemotherapy. This is the fi rst case of lymphoma occurring in a patient of psoriasis treated with low-dose MTX.
INTRODUCTION INTRODUCTION
Low dose methotrexate (MTX) (7.5-15 mg weekly) has emerged as the first choice of therapy for patients with resistant and widespread, chronic plaque psoriasis.
[1] Many studies have suggested an increased risk of lymphoma in patients with rheumatoid arthritis treated with low doses of MTX. [2] [3] [4] Although a variety of lymphoproliferative disorders have been described in the setting of methotrexate therapy for rheumatoid arthritis, cases of Hodgkin's disease (HD) have rarely been reported. Recognition of these lymphoproliferative disorders is clinically important because a subset of these neoplasms may completely resolve with discontinuation of methotrexate, thereby obviating the need for chemotherapy or radiation therapy.
[5] An increased risk of lymphoma is described in patients treated with immunosuppressants such as azathioprine, cyclophosphamide, cyclosporine, and steroids. [6] [7] We report here a case of Hodgkin's lymphoma months during this period. Bone marrow biopsy showed evidence of metastatic Hodgkin's disease in the bone marrow. Ultrasonography of the abdomen showed multiple, hepatic, hypoechoic lesions that resembled lymphoma. A computerized tomography (CT) scan of the neck and abdomen showed multiple, enlarged lymph nodes [Figures 2 and 3] . High-resolution CT (HRCT) of the chest revealed mediastinal lymphadenopathy. A positron emission tomography (PET) scan detected multiple areas of abnormal uptake in the right cervical, submandibular, and mediastinal group of lymph nodes, in the spleen and the bones.
MTX was discontinued and a chemotherapy regimen consisting of adriamycin 42 mg, bleomycin 17U, vinblastine 10 mg and dexamethasone 8 mg was given intravenously once a month by an oncologist. There was complete clinical remission as evident on X-rays after twelve cycles of chemotherapy.
DISCUSSION DISCUSSION
Several cases of Hodgkin's lymphoma have been reported following low-dose MTX therapy for various autoimmune conditions that include rheumatoid arthritis (RA), dermatomyositis, and inflammatory bowel disease. [8] [9] [10] [11] However, no case of Hodgkin's lymphoma following lowdose MTX therapy for psoriasis has been reported to date. This is important because, the compromised immune status due to the disease process itself is believed to play some role in the development of Hodgkin's disease in patients of RA treated with MTX.
[12] Such general compromise of immunity is not known in patients with psoriasis. The widely accepted hypothesis for the development of these tumors is that there is a lack of immune surveillance in these patients who are on immunosuppressive agents. This allows proliferation of Epstein Barr virus (EBV)-transformed B lymphocytes. However, virological studies were not done in our case. [9] There are various reports of lymphomas developing after low-dose MTX administered for different diseases [ Table 1 ]. The mean age at the onset of lymphoma in a threeyear prospective study conducted by Mariette et al, in 2002 in France was 63 years.
[5] The cumulative dose of MTX was 2.2 g in this study whereas in our case, it was about 1.5 g. In this study, a high incidence of HD was observed in RA treated with MTX, whereas no significant increased risk was found of non-Hodgkin's lymphoma (NHL). Hodgkin's disease, most often in association with EBV infection, is frequent in immunosuppressed patients.
[5] Kamel et al, reported Hodgkin's disease (four cases) and lymphoproliferations resembling Hodgkin's disease (four cases) that developed after receiving methotrexate for various disorders.
[9] All three patients with lymphoproliferations resembling HD on whom follow-up was available, experienced tumor regression with methotrexate withdrawal, with or without steroids. All three patients with HD on whom follow-up was available, were free of disease following chemotherapy or radiation therapy.
In view of the above reports, it is surprising that no cases of lymphoma have been reported in psoriasis patients treated with long-term, low-dose methotrexate. In fact, a retrospective-prospective analysis conducted by Balin et al, in 2005 psoriasis patients treated with MTX found no increased incidence of internal malignancies in these patients.
[13] In a large study on 248 patients, Nyfors et al, observed the frequency of malignant neoplasms in psoriatics (mean follow up period = 7 years) treated with long-term MTX. [14] Ten malignant neoplasms were seen during the period of follow-up in those 248 patients. These included seven females with ovarian (3), breast (2), and pancreatic (1) cancers and lymphoma (1) and three males with esophageal (1) and scrotal (1) cancers and lymphoma (1). The types of lymphomas encountered were not specified. However, they were concluded that methotrexate therapy used in the treatment of psoriasis does not seem to contribute to the development of malignant neoplasms.
[14] A similar conclusion was drawn by Stern et al. who evaluated the risk of noncutaneous and cutaneous malignancy associated with exposure to methotrexate.
[15] Although 26 cases of noncutaneous cancer were encountered in this study, the 104 matched controls observed also showed a similar incidence of malignancy. Hence, they concluded that there was no association between the development of noncutaneous malignancy and exposure to methotrexate. It has been hypothesized that psoriasis itself is associated with lymphomas. [16] [17] [18] [19] However, most studies have shown that the risk of lymphoma in psoriasis patients is not greater than that in the general population.
[16] The latest study conducted by Gelfand et al, to estimate the risk of lymphoma in patients with psoriasis suggested that the absolute risk of lymphoma attributable to psoriasis is low. [20] However, the present case indicates that the last has not been said on this issue and more long-term studies, including those from India, are needed. Our case is the first reported instance from India of methotrexate-associated lymphoma. The rapid response of the tumor to chemotherapy and the withdrawal of MTX in our case, suggests that MTX therapy was a factor in the generation of the tumor.
Many dermatologists use MTX as the first line of therapy in recalcitrant plaque type psoriasis. The rapid response to such therapy coupled with its simplicity and low cost has made it popular in India and has increased chances of selfmedication. Such extended therapy may make psoriatic patients prone to lymphoproliferative diseases. Hence, in spite of the ease of therapy, MTX should be used with caution in psoriasis. Regular follow-up in such cases should not only include evaluations for liver and bone marrow toxicity, but also for early detection of lymphoma, particularly after the initial anxieties about tolerance are alleviated. Thus, a detailed clinical examination for lymph node enlargement is considered absolutely necessary at long term followup visits. Aggressive investigation of any unexplained lymphadenopathy by fine needle aspiration cytology, and if required, lymph node biopsy, is also necessary. This would go a long way in detecting a rare though serious and frequently reversible side effect of MTX therapy.
